What Happened

Structure Therapeutics dosed first patients in Phase 3 ACCOMPLISH trials for aleniglipron, its oral GLP-1 receptor agonist for obesity. The company has $1.3B cash runway through 2028 and appointed John Berrios, a GLP-1 commercialization veteran, as Chief Commercial Officer.

Who Is Affected

Competitors in the obesity drug market (Novo Nordisk, Eli Lilly) now face a potential oral alternative to injectable GLP-1s. Payers and providers tracking oral obesity treatments should monitor Phase 3 data expected in H2 2026.

Market Impact

• Advances first oral small molecule GLP-1 agonist to Phase 3
• Dual amylin/calcitonin receptor agonist ACCG-2671 entering MAD trials in Q3 2026
• $100M+ quarterly R&D burn rate signals aggressive pipeline advancement

What to Watch

Topline 72-week aleniglipron data in Q3 2026 and body composition/T2D data in Q4 2026. Phase 1 data for ACCG-2671 and initiation of combination GLP-1/amylin trials expected late 2026.

Related coverage

• Corvus Eczema Trial Expected to Enroll About 200 Patients
• Trevi initiates chronic-cough trial targeting 2–3M U.S. patients
• Ollin Biosciences to Present OLN324 Data for DME and wAMD at ASRS 2026
• Cadrenal Therapeutics' CAD-1005 shows >25% reduction in HIT thrombotic events